A$0.036 CDX.AX CardieX Limited ASX 28 Jan 2026: Oversold bounce, watch A$0.06
CDX.AX stock closed at A$0.036 on 28 Jan 2026 after a shallow intraday range (Day Low A$0.035, Day High A$0.038). CardieX Limited (CDX.AX) has fallen 63.64% YTD and trades well below its 200-day average of A$0.06546, setting up an oversold bounce opportunity if buying volume returns. We examine price drivers, cash metrics, and technical triggers that could deliver a short-term rebound while highlighting why fundamental weakness keeps longer-term risk elevated.
Price action & short-term setup for CDX.AX stock
CDX.AX stock is at A$0.036 with trade volume 176,535 shares versus an average of 458,209.00. The stock opened at A$0.038 and finished flat versus prior close, signalling short-term indecision. The immediate technical objective on a bounce is resistance between A$0.060 and A$0.080, with the 50-day average at A$0.03212 acting as a nearer support. A rebound above A$0.060 on higher volume would confirm an oversold bounce trade.
Fundamentals & valuation snapshot for CDX.AX stock
CardieX Limited operates in Healthcare (Medical – Devices) and reports trailing EPS -0.04 and PE -0.90, reflecting current losses. Market cap is A$19,802,891.00 and shares outstanding are 550,080,317.00. Key ratios include Price/Sales 3.15, Price/Book 2.65, current ratio 1.56, and debt/equity 0.66. Revenue per share is 0.015 and book value per share is 0.01359, showing thin asset coverage and negative profitability that keep valuation stretched versus larger healthcare peers.
Technical and volume signals for CDX.AX stock
Short-term indicators show the stock is oversold versus its 200-day average A$0.06546 and 50-day average A$0.03212. On-chain technicals are muted but Keltner channel mid is A$0.030 and relative volume is 0.39, indicating lower participation. A meaningful oversold bounce needs a volume surge toward the average 458,209.00 to validate strength and push price above A$0.060. Failure to attract volume would likely resume the downtrend.
Meyka AI rating and model forecast for CDX.AX stock
Meyka AI rates CDX.AX with a score out of 100: 59.95 (C+, HOLD). This grade factors S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst signals. Meyka AI’s forecast model projects a 12-month price of A$0.02288, implying -36.46% versus current A$0.036; forecasts are model-based projections and not guarantees. We present a short-term bounce target A$0.060 and a downside support estimate A$0.020 to outline reward-to-risk.
Catalysts, sector context and risks for CDX.AX stock
Near-term catalysts include contract wins for SphygmoCor devices, regulatory approvals, or clinical trial service contracts that lift revenue visibility. Healthcare sector peers show average P/E 34.32, and CardieX’s performance lags larger med-device names. Major risks are persistent negative EPS, thin liquidity, and inventory turnover issues (days inventory 652.83), which could blunt any rally. Monitor ASX trading alerts and company releases for decisive news.
Final Thoughts
CDX.AX stock is a classic oversold-bounce candidate: the price sits at A$0.036, volume is below average, and the 200-day average A$0.06546 marks the mid-term trend. Short-term traders can watch a bounce above A$0.060 with rising volume as an entry confirmation; conservative traders should wait for clearer earnings or contract news from CardieX Limited. Meyka AI’s model projects A$0.02288 over the next 12 months, implying -36.46% versus the current price, which underlines the company’s longer-term downside risk. We assign a short-term bounce target A$0.060 and a longer-term downside level A$0.020 to frame risk management. Use stop-losses below recent support and track sector moves in Healthcare where peers trade at higher multiples. For quick reference and official releases visit CardieX’s site and coverage pages on Investing.com, and see our internal CDX.AX page for live alerts from Meyka AI’s real-time platform.
FAQs
Is CDX.AX stock a buy after the recent drop?
CDX.AX stock shows an oversold bounce setup, but fundamental weakness remains. Short-term traders may buy on a volume-backed move above A$0.060. Longer-term investors should wait for improving EPS or contract visibility before buying.
What is Meyka AI’s price forecast for CDX.AX stock?
Meyka AI’s forecast model projects A$0.02288 over 12 months, implying -36.46% from the current A$0.036. Forecasts are model-based projections and not guarantees.
Which levels matter for a CDX.AX stock trade?
Key levels: support near A$0.030 and A$0.020, resistance at A$0.060 and A$0.080. Volume near the average 458,209.00 confirms any sustainable bounce.
Where can I read CDX.AX stock news and filings?
Official company releases are on CardieX’s website and financial coverage appears on outlets such as Investing.com. Track both for regulatory updates and contract announcements.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
